Drug Profile
Naluzotan - Proximagen
Alternative Names: PRX-00023Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator EPIX Pharmaceuticals
- Developer EPIX Pharmaceuticals; National Institute of Neurological Disorders and Stroke; Proximagen
- Class Antidepressants; Anxiolytics; Piperazines; Small molecules; Sulfonamides
- Mechanism of Action 5-HT1A serotonin receptor agonists; Sigma-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Epilepsy
- Discontinued Drug-induced dyskinesia; Generalised anxiety disorder; Major depressive disorder
Most Recent Events
- 06 Oct 2017 National Institute of Neurological Disorders and Stroke terminates phase II trial in Epilepsy in USA (NCT01281956)
- 14 Aug 2012 Proximagen has been acquired by Upsher-Smith
- 05 Mar 2012 Discontinued - Phase-I for Drug-induced dyskinesia in USA (PO)